[1]齐玥,刘静,赵冬.从胆固醇代谢特点论降胆固醇药物联合应用[J].慢性病学杂志,2015,(03):240-244.
点击复制
从胆固醇代谢特点论降胆固醇药物联合应用(PDF)
《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]
- 卷:
- 期数:
- 2015年03期
- 页码:
- 240-244
- 栏目:
- 血脂专栏
- 出版日期:
- 2015-06-16
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- R541
- DOI:
- -
- 摘要:
- -
- Abstract:
- -
参考文献/References:
[1] 胡大一,仝其广.中国胆固醇教育计划一站在新的起跑线上[J]．
中国医药导刊,2008,4(10):479-480.
[2] Mihaylova B, Emberson J, Blackwell L, et al. The effects of
lowering ldl cholesterol with statin therapy in people at low risk
of vascular disease: Meta- analysis of individual data from 27
randomised trials [J]． Lancet, 2012,380(9841):581-590.
[3] 中国成人血脂异常防治指南制定联合委员会. 中国成人血脂异
常防治指南[J]． 中华心血管病杂志, 2007,35(5):390-419.
[4] Perk J, De Backer G, Gohlke H, et al. European guidelines
on cardiovascular disease prevention in clinical practice (version
2012). The fifth joint task force of the european society of cardi?
ology and other societies on cardiovascular disease prevention
in clinical practice (constituted by representatives of nine societ?
ies and by invited experts) [J]． European Heart Journal,
2012,33(17):1635-1701.
[5] Anderson TJ, Gregoire J, Hegele RA, et al. 2012 update of
the canadian cardiovascular society guidelines for the diagnosis
and treatment of dyslipidemia for the prevention of cardiovascu?
lar disease in the adult [J]．The Canadian Journal of Cardiology,
2013,29(2):151-167.
[6] Grundy SM. An international atherosclerosis society position
paper: Global recommendations for the management of dyslip?
idemia [J]． Journal of Clinical Lipidology,2013,7(6):561-
565.
[7] Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/
AHA guideline on the treatment of blood cholesterol to reduce
atherosclerotic cardiovascular risk in adults: A report of the
american college of cardiology/american heart association task
force on practice guidelines [J]．Journal of the American Col?
lege of Cardiology,2014,63(25 Pt B):2889-2934.
[8] Santos RD, Waters DD, Tarasenko L, et al. A comparison of
non-hdl and ldl cholesterol goal attainment in a large, multina?
tional patient population: The lipid treatment assessment proj?
ect 2 [J]． Atherosclerosis,2012,224(1):150-153.
[9] LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid
lowering with atorvastatin in patients with stable coronary dis?
ease [J]．The New England Journal of Medicine, 2005, 352
(14):1425-1435.
[10] Delahoy PJ, Magliano DJ, Webb K, et al. The relationship be?
tween reduction in low- density lipoprotein cholesterol by
statins and reduction in risk of cardiovascular outcomes: An up?
dated meta-analysis [J]．Clinical Therapeutics, 2009, 31(2):
236-244.
[11] Nissinen MJ, Miettinen TE, Gylling H, et al. Applicability of
non- cholesterol sterols in predicting response in cholesterol
metabolism to simvastatin and fluvastatin treatment among hy?percholesterolemic men [J]． Nutrition, Metabolism, and
Cardiovascular Diseases, 2010, 20(5):308-316.
[12] Plat J, Mensink RP. Plant stanol and sterol esters in the control
of blood cholesterol levels: Mechanism and safety aspects [J]．
The American Journal of Cardiology, 2005, 96(1A):15D-22D
[13] Miettinen TA, Gylling H, Viikari J, et al. Synthesis and ab?
sorption of cholesterol in Finnish boys by serum non-cholester?
ol sterols: The cardiovascular risk in young Finns study [J]．
Atherosclerosis, 2008, 200(1):177-183.
[14] van Himbergen TM, Matthan NR, Resteghini NA, et al.
Comparison of the effects of maximal dose atorvastatin and ro?
suvastatin therapy on cholesterol synthesis and absorption mark?
ers [J]．Journal of Lipid Research,2009,50(4):730-739.
[15] Jakulj L, Vissers MN, Groen AK, et al. Baseline cholesterol
absorption and the response to ezetimibe/simvastatin therapy:
A post- hoc analysis of the enhance trial [J]．Journal of Lipid
Research, 2010, 51(4):755-762.
[16] Qi Y, Liu J, Ma C, et al. Association between cholesterol syn?
thesis/absorption markers and effects of cholesterol lowering
by atorvastatin among patients with high risk of coronary heart
disease [J]． Journal of Lipid Research, 2013, 54(11):3189-
3197.
[17] Gylling H, Miettinen TA. Baseline intestinal absorption and
synthesis of cholesterol regulate its response to hypolipidaemic
treatments in coronary patients [J]． Atherosclerosis, 2002,
160(2):477-481.
[18] Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intesti?
nal cholesterol absorption by ezetimibe in humans [J]．Circu?
lation, 2002, 106(15):1943-1948.
[19] Seedorf U, Engel T, Lueken A, et al. Cholesterol absorption
inhibitor ezetimibe blocks uptake of oxidized ldl in human mac?
rophages [J]． Biochemical and Biophysical Research Com?
munications, 2004, 320(4):1337-1341.
[20] Kramer W, Girbig F, Corsiero D, et al. Aminopeptidase n
(cd13) is a molecular target of the cholesterol absorption inhibi?
tor ezetimibe in the enterocyte brush border membrane [J]．
The Journal of Biological Chemistry, 2005, 280(2):1306-1320.
[21] Lakoski SG, Xu F, Vega GL, et al. Indices of cholesterol me?
tabolism and relative responsiveness to ezetimibe and simvas?
tatin [J]．The Journal of Clinical Endocrinology and Metabo?
lism, 2010, 95(2):800-809.
[22] Okada K, Iwahashi N, Endo T, et al. Long- term effects of
ezetimibe-plus-statin therapy on low-density lipoprotein cho?
lesterol levels as compared with double- dose statin therapy in
patients with coronary artery disease [J]． Atherosclerosis,
2012, 224(2):454-456.
[23] Sasaki J, Otonari T, Sawayama Y, et al. Double- dose
pravastatin versus add- on ezetimibe with low- dose pravas?
tatin - effects on ldl cholesterol, cholesterol absorption, and
cholesterol synthesis in Japanese patients with hypercholester?
olemia (peas study) [J]． Journal of Atherosclerosis and
Thrombosis, 2012, 19(5):485-493.
[24] Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezeti?
mibe coadministered with atorvastatin or simvastatin in patients
with homozygous familial hypercholesterolemia [J]． Circula?
tion, 2002, 105(21):2469-2475.
[25] Mikhailidis DP, Lawson RW, McCormick AL, et al. Compar?
ative efficacy of the addition of ezetimibe to statin vs statin titra?
tion in patients with hypercholesterolaemia: Systematic review
and meta-analysis [J]． Current Medical Research and Opin?
ion, 2011, 27(6):1191-1210.
[26] Gudzune KA, Monroe AK, Sharma R, et al. Effectiveness of
combination therapy with statin and another lipid- modifying
agent compared with intensified statin monotherapy: A system ?
atic review [J]．Annals of Internal Medicine, 2014, 160(7):
468-476.
[27] Al- Jahdali H. Prevalence of sleep apnea and excessive day
time sleepiness in patients with end-stage renal disease on dial?
ysis [J]．Saudi Journal of Kidney Diseases and Transplanta?
tion, 2012, 23(2):251-261.
[28] Nakamura T, Hirano M, Kitta Y, et al. A comparison of the
efficacy of combined ezetimibe and statin therapy with doubling
of statin dose in patients with remnant lipoproteinemia on previ?
ous statin therapy [J]． Journal of Cardiology, 2012, 60(1):
12-17.
[29] Goldberg AC, Sapre A, Liu J, et al. Efficacy and safety of
ezetimibe coadministered with simvastatin in patients with pri?
mary hypercholesterolemia: A randomized, double-blind, pla?
cebo- controlled trial [J]． Mayo Clinic Proceedings, 2004,
79(5):620-629.
[30] Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or
without ezetimibe in familial hypercholesterolemia [J]． The
New England Journal of Medicine, 2008, 358(14):1431-1443
[31] Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid
lowering with simvastatin and ezetimibe in aortic stenosis [J]．
The New England Journal of Medicine, 2008, 359(13):1343-
1356.
[32] Baigent C, Landray MJ, Reith C, et al. The effects of lower?
ing ldl cholesterol with simvastatin plus ezetimibe in patients
with chronic kidney disease (study of heart and renal protec?
tion): A randomised placebo- controlled trial [J]． Lancet,
2011, 377(9784):2181-2192.
[33] DiNicolantonio JJ, Chatterjee S, Lavie CJ, et al. Ezetimibe
plus moderate dose simvastatin after acute coronary syndrome:
What are we improveing on [J]． The American Journal of
Medicine. 2015 Feb 27. pii: S0002- 9343(15)00166- 7. doi:
10.1016/j, amjmed, 2015.01.034.
备注/Memo
- 备注/Memo:
- 基金项目：国家自然科学基金面上项目（81170266）；北 京市优秀人才培养资助青年拔尖个人项目 （2014000021223ZK29） 作者简介：齐玥，副研究员，理学博士，心血管疾病的病 因学和转化医学研究 通信作者：赵冬，E-mail：deezhao@vip.sina.com
常用功能
统计/Statistics
- 摘要浏览/Viewed2395
- 全文下载/Downloads1769
- 评论/Comments
